Angiogenesis as a therapeutic target
The DOI matches its Crossref record; 103 of the 103 references it cites were found in a registry or an index.
Abstract
Inhibiting angiogenesis is a promising strategy for treatment of cancer and several other disorders, including age-related macular degeneration. Major progress towards a treatment has been achieved over the past few years, and the first antiangiogenic agents have been recently approved for use in several countries. Therapeutic angiogenesis (promoting new vessel growth to treat ischaemic disorders) is an exciting frontier of cardiovascular medicine, but further understanding of the mechanisms of vascular morphogenesis is needed first.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“As compared to the traditional transwell method, the monolayer design also has the added advantage of easily generating shear stress.”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [106]
In the citing paper
“This monolayer approach is very effective in applications where cylindrical vessel geometry of blood vessels is not very essential to the study, such as in the testing of drugs which prevent cancer cell migration because this method is high throughput and simple to fabricate [106].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [106]
In the citing paper
“Shear stress helps cells arrange themselves to establish the barrier function [106].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [106]
Citations
Cites
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968 · cited 1×
“This followed from a phase III study showing a survival benefi”
BackgroundSelf-citationTumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
The biology of VEGF and its receptors
Ferrara, N., Gerber, H.-P., & LeCouter, J. (2003) · Nature Medicine · doi:10.1038/nm0603-669 · Cited by 9,591 · cited 1×
“So far, VEGF-A and its receptors are the best-characterized signalling pathway in developmental angiogenesi”
BackgroundSelf-citationIsolation of Putative Progenitor Endothelial Cells for Angiogenesis
Asahara, T., Murohara, T., Sullivan, A., Silver, M., van der Zee, R., Li, T., Witzenbichler, B., Schatteman, G., & Isner, J. M. (1997) · Science · doi:10.1126/science.275.5302.964 · Cited by 8,725 · cited 1×
“reported the isolation of putative EPC from human peripheral blood, on the basis of cell-surface expression of CD34 and other endothelial marker”
BackgroundNormalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527 · cited 1×
“An alternative hypothesis has been proposed by Jai”
BackgroundTrastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Davidson, N. E., Tan-Chiu, E., Martino, S., Paik, S., Kaufman, P. A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052122 · Cited by 5,356
Endostatin: an endogenous inhibitor of angiogenesis and tumor growth
O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., & Folkman, J. (1997) · Cell · doi:10.1016/s0092-8674(00)81848-6 · Cited by 4,486 · cited 1×
“Several fragments of larger proteins have been described as endogenous inhibitors of angiogenesis including endostati”
BackgroundOrimo, A., Gupta, P. B., Sgroi, D. C., Arenzana-Seisdedos, F., Delaunay, T., Naeem, R., Carey, V. J., Richardson, A. L., & Weinberg, R. A. (2005) · Cell · doi:10.1016/j.cell.2005.02.034 · Cited by 3,759
Vascular-specific growth factors and blood vessel formation
Yancopoulos, G. D., Davis, S., Gale, N. W., Rudge, J. S., Wiegand, S. J., & Holash, J. (2000) · Nature · doi:10.1038/35025215 · Cited by 3,699 · cited 1×
“So far, VEGF-A and its receptors are the best-characterized signalling pathway in developmental angiogenesi”
BackgroundVascular Endothelial Growth Factor: Basic Science and Clinical Progress
Ferrara, N. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0027 · Cited by 3,687
Self-citation
Research works printed but not linked: 1
- Prewett, M. et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis. Cancer Res. 59, 5209–5218 (1999).
Cited by
Items 301–400 of 1,007
Ligand‐Stimulated VEGFR2 Signaling is Regulated by Co‐Ordinated Trafficking and Proteolysis
Bruns, A. F., Herbert, S. P., Odell, A. F., Jopling, H. M., Hooper, N. M., Zachary, I. C., Walker, J. H., & Ponnambalam, S. (2010) · Traffic · doi:10.1111/j.1600-0854.2009.01001.x · Cited by 135
Sphingosine-1-phosphate signaling and biological activities in the cardiovascular system
Takuwa, Y., Okamoto, Y., Yoshioka, K., & Takuwa, N. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2008.04.003 · Cited by 136
“One of the drawbacks in previous trials of angiogenic therapy is local tissue edema due to vascular leakage [47].”
BackgroundAdipose tissue immunity and cancer
Catalán, V., Gómez‐Ambrosi, J., Rodríguez, A., & Frühbeck, G. (2013) · Frontiers in Physiology · doi:10.3389/fphys.2013.00275 · Cited by 146
“In this regard, many cytokines produced by adipose tissue show angiogenic activities such as leptin, TNF-α, IL-6, IL-8, vascular endothelial growth factor (VEGF) and tumor growth factor β (TGF-β) (Ferrara and Kerbel, 2005; Ye, 2009; Gómez-Ambrosi et al., 2010).”
BackgroundThe effect of aging on the cutaneous microvasculature
Bentov, I., & Reed, M. J. (2015) · Microvascular Research · doi:10.1016/j.mvr.2015.04.004 · Cited by 175
Development of PLGA-coated β-TCP scaffolds containing VEGF for bone tissue engineering
Khojasteh, A., Fahimipour, F., Eslaminejad, M. B., Jafarian, M., Jahangir, S., Bastami, F., Tahriri, M., Karkhaneh, A., & Tayebi, L. (2016) · Materials Science and Engineering C · doi:10.1016/j.msec.2016.07.011 · Cited by 139
Peptide‐Based Multifunctional Nanomaterials for Tumor Imaging and Therapy
Zhang, C., Wu, W. H., Li, R., Qiu, W., Zhuang, Z., Cheng, S., & Zhang, X. (2018) · Advanced Functional Materials · doi:10.1002/adfm.201804492 · Cited by 137
Kwon, G. T., Cho, H., Chung, W., Park, K.-K., Moon, A., & Park, J. H. Y. (2008) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2008.06.005 · Cited by 135
“The formation of a tumor vasculature is a crucial reaction supporting tumor growth [54], and VEGF plays a major role in tumor angiogenesis, so inhibiting VEGF production is a promising strategy for the treatment of cancer [55].”
BackgroundPang, X., Yi, T., Yi, Z., Cho, S., Qu, W., Pinkaew, D., Fujise, K., & Liu, M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2531 · Cited by 137
“Because VEGF is a major inducer for the formation of tumor vasculature (34, 35), our results show that morelloflavone inhibits tumor growth in vivo via their antiangiogenic activity at a much lower concentration and much earlier than their cytotoxicity effects on tumor cells.”
Vallée, A., Guillevin, R., & Vallée, J.-N. (2017) · Reviews in the Neurosciences · doi:10.1515/revneuro-2017-0032 · Cited by 150
“Platelet-derived growth factor (PDGF) secretion recruits pericytes to the site of newly forming vessels and participates in establishing a new basement membrane with the aid of the ANG/TIE pathway (Lindahl et al., 1997; Ferrara and Kerbel, 2005).”
BackgroundEndothelium-Microenvironment Interactions in the Developing Embryo and in the Adult
Red‐Horse, K., Crawford, Y., Shojaei, F., & Ferrara, N. (2007) · Developmental Cell · doi:10.1016/j.devcel.2007.01.013 · Cited by 141
“This strategy has produced promising therapies capable of treating cancer and angiogenic eye disease (Ferrara and Kerbel, 2005).”
BackgroundInfluentialSelf-citationHlushchuk, R., Riesterer, O., Baum, O., Wood, J. M., Gruber, G., Pruschy, M. N., & Djonov, V. (2008) · American Journal Of Pathology · doi:10.2353/ajpath.2008.071131 · Cited by 153
“Many human neoplasms and animal tumor models express high mRNA and protein levels of VEGF.(2,8,9) Inhibition of VEGF or of its receptors should block the downstream cascade and interfere with its pro-angiogenic effects and thereby block tumor vascularization.”
BackgroundInjectable hyaluronic acid-tyramine hydrogels incorporating interferon-α2a for liver cancer therapy
Xu, K., Lee, F., Gao, S. J., Chung, J. E., Yano, H., & Kurisawa, M. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.01.008 · Cited by 134
Huang, J., Ren, J., Chen, G., Li, Z., Liu, Y., Wang, G., & Wu, X. (2018) · Materials Science and Engineering C · doi:10.1016/j.msec.2018.04.009 · Cited by 137
CCN family proteins and angiogenesis: from embryo to adulthood
Kubota, S., & Takigawa, M. (2006) · Angiogenesis · doi:10.1007/s10456-006-9058-5 · Cited by 144
“nancies [87].”
Tumor Angiogenesis and Vascular Patterning: A Mathematical Model
Travasso, R. D. M., Poiré, E. C., Castro, M., Rodríguez-Manzaneque, J. C., & Hernández-Machado, A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019989 · Cited by 156
Current treatments for non-small cell lung cancer
Guo, Q., Liu, L., Chen, Z., Fan, Y., Zhou, Y., Yuan, Z., & Zhang, W. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.945102 · Cited by 171
Ferro, V., Liu, L.-G., Johnstone, K., Wimmer, N., Karoli, T., Handley, P. N., Rowley, J. A., Dredge, K., Li, C.-P., Hammond, E., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm201708h · Cited by 118
Vascular RhoJ is an effective and selective target for tumor angiogenesis and vascular disruption
Kim, C., Yang, H., Fukushima, Y., Saw, P. E., Lee, J., Park, J.-S., Park, I., Jung, J., Kataoka, H., Lee, D., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2013.12.010 · Cited by 131
“102 Cancer Cell 25, 102–117, January 13, 2014 ª2014 Elsevier Inc. inhibiting agents (AIAs) in the past decade (Ellis and Hicklin, 2008; Ferrara and Kerbel, 2005; Sennino and McDonald, 2012), many of which target vascular endothelial growth factor (VEGF) and its receptors and have proved to be…”
BackgroundFoxs and Ets in the transcriptional regulation of endothelial cell differentiation and angiogenesis.
Dejana, E., Taddei, A., & Randi, A. (2007) · Biochimica et Biophysica Acta · doi:10.1016/j.bbcan.2007.05.003 · Cited by 146
Eskander, R. N., & Tewari, K. S. (2013) · Gynecologic Oncology · doi:10.1016/j.ygyno.2013.11.029 · Cited by 133
“and have been identified as potential targets for drug development [39,40].”
BackgroundAo, A., Wang, H., Kamarajugadda, S., & Lu, J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711677105 · Cited by 131
“Disruption of individual HIF downstream events such as angiogenesis and glycolysis has shown promising efficacy (6, 11).”
BackgroundSpatiotemporal control over growth factor signaling for therapeutic neovascularization☆
Cao, L., & Mooney, D. J. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.08.012 · Cited by 146
“These vascular functions require the formation of a new vasculature in the vast majority of tissue regeneration and tissue engineering processes [1,2].”
BackgroundOverview of anti-angiogenic agents in development for ovarian cancer
Burger, R. A. (2011) · Gynecologic Oncology · doi:10.1016/j.ygyno.2010.11.035 · Cited by 150
“VEGFR2 directly mediates the angiogenic- and permeability-enhancing effects of VEGF, whereas VEGFR1 may play a role in promoting angiogenesis by recruiting monocytes and other bone marrow-derived cells to the tumor vasculature [8].”
BackgroundGPER Mediates Activation of HIF1α/VEGF Signaling by Estrogens
De Francesco, E. M., Pellegrino, M., Santolla, M. F., Lappano, R., Ricchio, E., Abonante, S., & Maggiolini, M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3590 · Cited by 130
Ayoubi‐Joshaghani, M. H., Seidi, K., Azizi, M., Jaymand, M., Javaheri, T., Jahanban‐Esfahlan, R., & Hamblin, M. R. (2020) · Advanced Functional Materials · doi:10.1002/adfm.202004098 · Cited by 137
The Fluid Mechanics of Cancer and Its Therapy
Koumoutsakos, P., Pivkin, I., & Milde, F. (2013) · Annual Review of Fluid Mechanics · doi:10.1146/annurev-fluid-120710-101102 · Cited by 129
“Angiogenesis is one of the hallmarks of cancer (Hanahan & Weinberg 2000), an indication of a malignant development in primary and metastatic tumors, and, as such, a therapeutic target (Ferrara & Kerbel 2005, Folkman 2006).”
BackgroundFibroblast growth factor 2 regulates endothelial cell sensitivity to sunitinib
Welti, J. C., Gourlaouen, M., Powles, T. B., Kudahetti, S. C., Wilson, P. A., Berney, D. M., & Reynolds, A. R. (2010) · Oncogene · doi:10.1038/onc.2010.503 · Cited by 141
“Numerous inhibitors of the VEGF signalling axis have been developed, including the VEGF-neutralising antibody, bevacizumab, and VEGF receptor tyrosine kinase inhibitors, such as sunitinib (Ferrara et al., 2004; Ferrara and Kerbel, 2005; Ellis and Hicklin, 2008; Kerbel, 2008).”
Tumor Angiogenesis and Anti-angiogenic Therapy
Kubota, Y. (2012) · The Keio Journal of Medicine · doi:10.2302/kjm.61.47 · Cited by 128
Context-dependent signaling defines roles of BMP9 and BMP10 in embryonic and postnatal development
Chen, H., Ridgway, J. B., Sai, T., Lai, J. J., Warming, S., Chen, H., Roose‐Girma, M., Zhang, G., Shou, W., & Yan, M. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1306074110 · Cited by 147
Angiogenesis in cancer: molecular mechanisms, clinical impact
Eichhorn, M., Kleespies, A., Angele, M. K., Jauch, K. ‐., & Bruns, C. J. (2007) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-007-0150-0 · Cited by 153
“Endothelial progenitor cells, the cross talk between angiogenic factors and their receptors and the interaction between vasculogenesis and lymphangiogenesis are all factors that may contribute to the switch [7].”
Bell‐McGuinn, K. M., Garfall, A. L., Bogyo, M. S., Hanahan, D., & Joyce, J. A. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0602 · Cited by 135
Vallée, A., & Lecarpentier, Y. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072440 · Cited by 141
“VEGF may be due to physiological activators, including inflammation and hypoxia [49,50].”
BackgroundDorrell, M. I., Aguilar, E., Jacobson, R., Yanes, O., Gariano, R., Heckenlively, J., Banin, E., Ramirez, G. A., Gasmi, M., Bird, A., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci35977 · Cited by 127
Yoshida, G. J., Azuma, A., Miura, Y., & Orimo, A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092256 · Cited by 126
“Inhibition of VEGF-A is effective in treating several human carcinomas [92].”
BackgroundBioreducible BPEI-SS-PEG-cNGR polymer as a tumor targeted nonviral gene carrier
Son, S., Singha, K., & Kim, W. J. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.04.047 · Cited by 126
The functional role of platelets in the regulation of angiogenesis
Walsh, T. G., Metharom, P., & Berndt, M. C. (2014) · Platelets · doi:10.3109/09537104.2014.909022 · Cited by 150
“loss of healing/regeneration, which are hallmarks of myocardial ischemia [120], neurodegeneration [121] and preeclampsia [122].”
BackgroundMacedo, L. T., da Costa Lima, A. B., & Sasse, A. D. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-89 · Cited by 126
“One of the main pathways associated with the anti-angiogenic process is the vascular endothelial growth factor (VEGF) family, with high expression of its receptors observed not only in colorectal neoplasms, but in a wide variety of distinct tumours [4].”
BackgroundChen, S., Yang, K., Tuguntaev, R. G., Mozhi, A., Zhang, J., Wang, P. C., & Liang, X.-J. (2016) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2015.10.020 · Cited by 126
The critical roles of m6A modification in metabolic abnormality and cardiovascular diseases
Zhang, B., Jiang, H., Dong, Z., Sun, A., & Ge, J. (2020) · Genes & Diseases · doi:10.1016/j.gendis.2020.07.011 · Cited by 134
Understanding tumor endothelial cell abnormalities to develop ideal anti‐angiogenic therapies
Hida, K., Hida, Y., & Shindoh, M. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2007.00704.x · Cited by 138
Sakurai, Y., Hatakeyama, H., Sato, Y., Hyodo, M., Akita, H., Ohga, N., Hida, K., & Harashima, H. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.10.003 · Cited by 130
Whole-Body Subcellular Multicolor Imaging of Tumor-Host Interaction and Drug Response in Real Time
Yang, M., Jiang, P., & Hoffman, R. M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4590 · Cited by 122
“Advantages to targeting the stroma cells are that the cells are genetically stable unlike cancer cells and are therefore less likely to develop drug resistance (18, 19).”
Usefulness of combining intermittent hypoxia and physical exercise in the treatment of obesity
Urdampilleta, A., González‐Muniesa, P., Portillo, M. P., & Martínez, J. A. (2011) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-011-0115-1 · Cited by 144
“Increases lung diffusion capacity for CO and O2 [149] Increases peripheral vasodilation [63] Angiogenesis [28, 47] Increases adrenergic system [85, 159]”
Oguro, Y., Miyamoto, N., Okada, K., Takagi, T., Iwata, H., Awazu, Y., Miki, H., Hori, A., Kamiyama, K., & Imamura, S. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.08.017 · Cited by 126
Zebrafish models of dyslipidemia: relevance to atherosclerosis and angiogenesis
Fang, L., Liu, C., & Miller, Y. I. (2013) · Translational research · doi:10.1016/j.trsl.2013.09.004 · Cited by 130
Targeting the tumour microenvironment in ovarian cancer
Hansen, J. M., Coleman, R. L., & Sood, A. K. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2015.12.016 · Cited by 123
“In addition to these pathways, PDGF, epidermal growth factor (EGF), angiopoietins, and hepatocyte growth factor are growth factors known to contribute to tumour angiogenesis [57].”
Integrin Inhibitors Reaching the Clinic
Stupp, R., & Ruegg, C. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.8376 · Cited by 122
Regulation and role of endogenously produced hydrogen sulfide in angiogenesis
Katsouda, A., Bibli, S., Pyriochou, A., Szabó, C., & Papapetropoulos, A. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.08.026 · Cited by 128
Vascular Normalization: A New Window Opened for Cancer Therapies
Yang, T., Xiao, H., Liu, X., Wang, Z., Zhang, Q., Wei, N., & Guo, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.719836 · Cited by 141
Delta-like 4/Notch Signaling and Its Therapeutic Implications
Yan, M., & Plowman, G. D. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1393 · Cited by 121
A potent immunotoxin targeting fibroblast activation protein for treatment of breast cancer in mice
Fang, J., Xiao, L., Joo, K., Liu, Y., Zhang, C., Liu, S., Conti, P. S., Li, Z., & Wang, P. (2016) · International Journal of Cancer · doi:10.1002/ijc.29831 · Cited by 120
“MMPs and VEGF play important roles in vasculogenesis and angiogenesis.(38) Immunotoxin aFAP-PE38 reduced the expression of VEGF and MMP-9, but not MMP-2.”
BackgroundBocca, P., Di Carlo, E., Caruana, I., Emionite, L., Cilli, M., De Angelis, B., Quintarelli, C., Pezzolo, A., Raffaghello, L., Morandi, F., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2017.1378843 · Cited by 119
“BEV is highly specific for human VEGF-A.19,22,24 BEV showed an extremely weak interaction with murine VEGF-A and failed to neutralize it in different bio-assays, including proliferation of mouse endothelial cells stimulated by murine VEGF.42 These findings support our working hypothesis that VEGF-A blockade occurred a…”
BackgroundRegulation of Vascular Endothelial Growth Factor Signaling by miR-200b
Choi, Y.-C., Yoon, S., Jeong, Y., Yoon, J., & Baek, K. (2011) · Molecules and Cells · doi:10.1007/s10059-011-1042-2 · Cited by 128
“Since angiogenesis is essential for tumor growth, inhibition of VEGF signaling using several strategies such as small molecule inhibitors, antibodies, VEGF-trap, and siRNA is a promising therapeutic approach for the treatment of cancer (Eskens, 2004; Ferrara and Kerbel, 2005).”
MethodChecco, J. W., Kreitler, D. F., Thomas, N. C., Belair, D. G., Rettko, N. J., Murphy, W. L., Forest, K. T., & Gellman, S. H. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1420380112 · Cited by 119
Therapeutic targeting of the prostate cancer microenvironment
Κάρλου, Μ., Tzelepi, V., & Efstathiou, E. (2010) · Nature Reviews Urology · doi:10.1038/nrurol.2010.134 · Cited by 130
Li, X., Tjwa, M., Hove, I. V., Enholm, B., Neven, E., Paavonen, K., Jeltsch, M., Juan, T. D., Sievers, R. E., Chorianopoulos, E., et al. (2008) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.107.158725 · Cited by 119
MicroRNA-9 Couples Brain Neurogenesis and Angiogenesis
Madelaine, R., Sloan, S. A., Huber, N., Notwell, J. H., Leung, L. C., Skariah, G., Halluin, C., Paşca, S. P., Bejerano, G., Krasnow, M. A., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.07.051 · Cited by 118
“A (Ferrara and Kerbel, 2005; Ruhrberg and Bautch, 2013).”
Structural and mechanistic insights into VEGF receptor 3 ligand binding and activation
Leppänen, V.-M., Tvorogov, D., Kisko, K., Prota, A. E., Jeltsch, M., Anisimov, A., Markovic-Mueller, S., Stuttfeld, E., Goldie, K. N., Ballmer-Hofer, K., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1301415110 · Cited by 122
Song, N., Huang, Y., Shi, H., Yuan, S., Ding, Y., Song, X., Fu, Y., & Luo, Y. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2007 · Cited by 122
Jeong, G. S., Han, S., Shin, Y., Kwon, G. H., Kamm, R. D., Lee, S.-H., & Chung, S. (2011) · Analytical Chemistry · doi:10.1021/ac202170e · Cited by 117
Reynolds, A. R. (2010) · Dose-Response · doi:10.2203/dose-response.09-049.reynolds · Cited by 132
“The VEGF signalling system appears to be a highly ‘druggable’ target and potent inhibitors of the VEGF signalling pathway have been developed (Ferrara et al. 2004; Ferrara and Kerbel 2005; Ellis and Hicklin 2008; Kerbel 2008).”
BackgroundShojaei, F., & Ferrara, N. (2008) · Drug Resistance Updates · doi:10.1016/j.drup.2008.09.001 · Cited by 131
Self-citationMicro-ultrasound for preclinical imaging
Foster, F. S., Hossack, J. A., & Adamson, S. L. (2011) · Interface Focus · doi:10.1098/rsfs.2011.0037 · Cited by 128
Phan, V. T., Wu, X., Cheng, J. H., Sheng, R. X., Chung, A. S., Zhuang, G., Tran, C., Song, Q., Kowanetz, M., Sambrone, A., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1303302110 · Cited by 116
Self-citationYadav, V. R., Prasad, S., Sung, B., Gelovani, J. G., Guha, S., Krishnan, S., & Aggarwal, B. B. (2011) · International Journal of Cancer · doi:10.1002/ijc.26251 · Cited by 118
“VEGF activates cellular signaling pathways by binding to its receptor tyrosine kinase, which promotes several events required for angiogenesis, including endothelial cell survival, proliferation and migration and vascular permeability.(35) In this study, AKBA downregulated the expression of VEGF in tumor tissues, indi…”
BackgroundLiang, W., Dennis, M. S., Stawicki, S. S., Chanthery, Y. H., Pan, Q., Chen, Y., Eigenbrot, C. W., Yin, J., Koch, A., Wu, X., et al. (2006) · Journal of Molecular Biology · doi:10.1016/j.jmb.2006.11.021 · Cited by 127
Self-citationLiu, F., Wang, J., Chang, A. K., Liu, B., Yang, L., Li, Q., Wang, P., & Zou, X. (2012) · Phytomedicine · doi:10.1016/j.phymed.2012.03.015 · Cited by 117
Dynamic contrast-enhanced magnetic resonance imaging and pharmacokinetic models in prostate cancer
Franiel, T., Hamm, B., & Hricak, H. (2010) · European Radiology · doi:10.1007/s00330-010-2037-7 · Cited by 115
“Several studies have demonstrated that inhibition of neovascularization of a malignant tumour significantly improves progression-free survival and disease-specific survival [98].”
BackgroundTumor Angiogenesis: Insights and Innovations
Nussenbaum, F., & Herman, I. M. (2010) · Journal of Oncology · doi:10.1155/2010/132641 · Cited by 116
“The loss of a VEGF allele always results in embryonic lethality [35].”
Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program
Maris, J. M., Courtright, J., Houghton, P. J., Morton, C. L., Gorlick, R. G., Kolb, E. A., Lock, R. B., Tajbakhsh, M., Reynolds, C. P., Keir, S. T., et al. (2007) · Pediatric Blood & Cancer · doi:10.1002/pbc.21232 · Cited by 119
“Therapeutic strategies to inhibit VEGF signaling have included soluble VEGF receptor decoys, aptamers, monoclonal antibodies, and small molecule inhibitors of receptor tyrosine kinases [12].”
BackgroundVilloutreix, B. O., Kuenemann, M. A., Poyet, J., Bruzzoni‐Giovanelli, H., Labbé, C., Lagorce, D., Sperandio, O., & Miteva, M. A. (2014) · Molecular Informatics · doi:10.1002/minf.201400040 · Cited by 116
Harnessing the hypoxia-inducible factor in cancer and ischemic disease
Brahimi-Horn, M. C., & Pouysségur, J. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2006.10.013 · Cited by 122
Ebos, J. M. L., Lee, C. R., Bogdanovic, E., Alami, J., Van Slyke, P., Francia, G., Xu, P., Mutsaers, A. J., Dumont, D. J., & Kerbel, R. S. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-3217 · Cited by 114
“angiogenesis is governed, in large part, by an array of growth factors, including those favoring or opposing new blood vessel capillary formation, many of which bind their cognate receptor tyrosine kinases (RTK) expressed on vascular endothelial cells and their bone marrow-derived progenitors (2).”
BackgroundSelf-citationDrug Insight: VEGF as a therapeutic target for breast cancer
Schneider, B. P., & Sledge, G. W. (2007) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0740 · Cited by 125
“VEGFR2 has intracellular tyrosine kinase activity and is considered to be the major mediator of the angiogenic properties of VEGFA”
BackgroundThe Angiomotins – From discovery to function
Moleirinho, S., Guerrant, W., & Kissil, J. L. (2014) · FEBS Letters · doi:10.1016/j.febslet.2014.02.006 · Cited by 112
Anti-angiogenic effect of siphonaxanthin from green alga, Codium fragile
Ganesan, P., Matsubara, K., Ohkubo, T., Tanaka, Y., Noda, K., Sugawara, T., & Hirata, T. (2010) · Phytomedicine · doi:10.1016/j.phymed.2010.05.005 · Cited by 112
“Variety of anti-angiogenic agents with diverse mechanism (several of which are not known) of action are currently in clinical trials (Ferrara and Kerbel, 2005).”
InfluentialEnsemble Analysis of Angiogenic Growth in Three-Dimensional Microfluidic Cell Cultures
Farahat, W. A., Wood, L. B., Zervantonakis, I. K., Schor, A., Ong, S., Neal, D., Kamm, R. D., & Asada, H. H. (2012) · PLoS ONE · doi:10.1371/journal.pone.0037333 · Cited by 113
Interleukin-8: A potent promoter of angiogenesis in gastric cancer
Shi, J., & WEI, P.-K. (2015) · Oncology Letters · doi:10.3892/ol.2015.4035 · Cited by 115
“The VEGF-VEGFR signaling system is important, not only in physiological angiogenesis from early embryonic to adult stages, but also in pathological angiogenesis, including in cancers (48-52).”
Hypoxia in cancer cell metabolism and pH regulation
Brahimi-Horn, M. C., & Pouysségur, J. (2007) · Essays in Biochemistry · doi:10.1042/bse0430165 · Cited by 113
Rowe, G. C., Raghuram, S., Jang, C., Nagy, J. A., Patten, I. S., Goyal, A., Chan, M. C., Liu, L. X., Jiang, A., Spokes, K. C., et al. (2014) · Circulation Research · doi:10.1161/circresaha.115.303829 · Cited by 114
Platelets Take Up the Monoclonal Antibody Bevacizumab
Verheul, H. M. W., Lolkema, M. P., Qian, D. Z., Hilkes, Y. H. A., Liapi, E. A., Akkerman, J. N., Пили, Р., & Voest, E. E. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0847 · Cited by 113
Molecular Recognition of Gangliosides and Their Potential for Cancer Immunotherapies
Krengel, U., & Bousquet, P. A. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00325 · Cited by 124
“Tumor cells produce and release the growth factor VEGF, stimulating the VEGFR, and ultimately resulting in proliferation and migration of vascular endothelial cells (64).”
BackgroundMahadev, K., Wu, X., Donnelly, S., Ouedraogo, R., Eckhart, A. D., & Goldstein, B. J. (2008) · Cardiovascular Research · doi:10.1093/cvr/cvn034 · Cited by 112
“Migration of endothelial cells contributes to diverse vascular physiology and pathology such as wound healing, restenosis in grafted and injured vessels and atherosclerosis.(8) Vascular endothelial growth factor (VEGF)(3) is involved in cellular mobilization via disruption of cell–cell and cell–substrate contacts and…”
BackgroundVerheul, H. M. W., Hammers, H. J., van Erp, K., Wei, Y., Sanni, T. B., Salumbides, B. C., Qian, D. Z., Yancopoulos, G. D., & Пили, Р. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2553 · Cited by 113
Bevacizumab in ovarian cancer: A critical review of phase III studies
Rossi, L., Verrico, M., Zaccarelli, E., Papa, A., Colonna, M., Strudel, M., Vici, P., Bianco, V., & Tomao, F. (2016) · Oncotarget · doi:10.18632/oncotarget.13310 · Cited by 112
Reddy, V. G., Reddy, T. S., Chetna, J., Reddy, M. S., Sultana, F., Akunuri, R., Bhargava, S. K., Włodkowic, D., Srihari, P., & Kamal, Ä. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111609 · Cited by 111
Palomero, J., Vegliante, M. C., Rodríguez, M. L., Eguileor, Á., Castellano, G., Planas‐Rigol, E., Jares, P., Ribera‐Cortada, I., Cid, M. C., Campo, E., et al. (2014) · Blood · doi:10.1182/blood-2014-04-569566 · Cited by 112
Vascular update: Morphogenesis, tumors, malformations, and molecular dimensions
Cohen, M. M. (2006) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.31333 · Cited by 113
Obligatory participation of macrophages in an angiopoietin 2-mediated cell death switch
Rao, S., Lobov, I. B., Vallance, J. E., Tsujikawa, K., Shiojima, I., Akunuru, S., Walsh, K., Benjamin, L. E., & Lang, R. A. (2007) · Development · doi:10.1242/dev.012187 · Cited by 113
“In diseases like AMD and cancer where macrophages play a prominent role, it will be interesting to determine whether macrophage production of Wnt ligands is a factor contributing to disease progression.”
BackgroundMarqués, L., Núñez-Córdoba, J. M., Aguado, L., Pretel, M., Boixeda, P., Nagore, E., Baselga, E., & Redondo, P. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.10.011 · Cited by 120
Endocan Expression and Localization in Human Glioblastomas
Maurage, C., Adam, E., Minéo, J.-F., Sarrazin, S., Debunne, M., Siminski, R.-M., Baroncini, M., Lassalle, P., Blond, S., & Delehedde, M. (2009) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3181a52a7f · Cited by 110
Treatment of Colorectal Cancer with and without Bevacizumab: A Phase III Study
Stathopoulos, G. P., Batziou, C., Trafalis, D. T., Koutantos, J., Batzios, S., Stathopoulos, J., Legakis, J., & Armakolas, A. (2010) · Oncology · doi:10.1159/000320520 · Cited by 119
“The VEGF receptor (VEGFR) family ligands, VEGF-1 and VEGF-2, are biologically related to angiogenesis, and VEGF-c and D-VEGFR-3 are associated with lymphangiogenesis. Tumor angiogenesis is complex in that many cell types and factors are involved: i.e. such as platelet-derived growth factor, b-fibroblast growth factor,…”
BackgroundEpigenetic silencing of miR-126 contributes to tumor invasion and angiogenesis in colorectal cancer
Zhang, Y., Wang, X., Xu, B., Wang, B., Wang, Z., Liang, Y., Zhou, J., Hu, J., & Jiang, B. (2013) · Oncology Reports · doi:10.3892/or.2013.2633 · Cited by 116
The role of CD44 in pathological angiogenesis
Chen, L., Fu, C., Zhang, Q., He, C., Zhang, F., & Wei, Q. (2020) · The FASEB Journal · doi:10.1096/fj.202000380rr · Cited by 122
De Luca, A., Gallo, M., Aldinucci, D., Ribatti, D., Lamura, L., D'Alessio, A., De Filippi, R., Pinto, A., & Normanno, N. (2011) · Journal of Cellular Physiology · doi:10.1002/jcp.22548 · Cited by 113
“This latter cell type plays an important role in cancer progression by promoting angiogenesis, epithelial to mesenchymal transition, and genetic instability (Hall et al., 2007).”
BackgroundLin, N., Li, X., Song, T., Wang, J., Meng, K., Yang, J., Hou, X., Dai, J., & Hu, Y. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.11.038 · Cited by 114
“It has been extensively tested in pre-clinical and clinical studies with a therapeutic goal [22,23].”
Cell therapies for therapeutic angiogenesis: back to the bench
Sieveking, D. P., & Ng, M. K. C. (2009) · Vascular Medicine · doi:10.1177/1358863x08098698 · Cited by 110
VEGF-B: A survival, or an angiogenic factor?
Li, X., Lee, C., Tang, Z., Zhang, F., Arjunan, P., Li, Y., Hou, X., Kumar, A., & Dong, L. (2009) · Cell Adhesion & Migration · doi:10.4161/cam.3.4.9459 · Cited by 112
Dønnem, T., Al‐Saad, S., Al-Shibli, K. I., Andersen, S., Busund, L., & Bremnes, R. M. (2008) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181834f52 · Cited by 116
Angiogenesis inhibition as a therapeutic strategy in non-small cell lung cancer (NSCLC).
Hall, R. D., Le, T. M., Haggstrom, D. E., & Gentzler, R. D. (2015) · PubMed · doi:10.3978/j.issn.2218-6751.2015.06.09 · Cited by 125
“Tumor angiogenesis is characterized by the formation of abnormal, tortuous, and poorly organized vessels with altered permeability (13,16).”
Background
Metadata
- Authors
- Ferrara, N., & Kerbel, R. S.
- Affiliations
- Genentech (US)
- Sunnybrook Health Science Centre (CA)
- Corresponding author
- Ferrara, Napoleone
- Venue
- Nature
- Published
- 2005-12
- Volume
- 438
- Issue
- 7070
- Pages
- 967-974
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2084740377
- Semantic Scholar
- 19591ab68a155b2d341266c48a9ef957bd4ba612
- Cited by
- 2,653
- References
- 102
- Citations by year
- 2026: 39 · 2025: 57 · 2024: 72 · 2023: 69 · 2022: 75 · 2021: 102 · 2020: 114 · 2019: 95 · 2018: 97 · 2017: 124 · 2016: 160 · 2015: 164 · 2014: 158 · 2013: 171 · 2012: 164
- FWCI
- 11.70
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institutes of Health
- Canadian Institutes of Health Research
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Lymphatic System and Diseases
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Keywords
- angiogenesis, anti-angiogenic therapy, therapeutic angiogenesis, cancer therapy, age-related macular degeneration, antiangiogenic drugs, vascular morphogenesis
- MeSH terms
- Animals, Bone Marrow Cells, Clinical Trials as Topic, Humans, Neoplasms, Neovascularization, Pathologic, Signal Transduction, Drug Resistance, Neoplasm, Angiogenesis Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.